COSCIENS Biopharma Inc. (LON:0UGB)
London · Delayed Price · Currency is GBP · Price in CAD 3.410
-0.790 (-18.81%)
At close: Nov 6, 2025
COSCIENS Biopharma Revenue
COSCIENS Biopharma had revenue of $1.48M USD in the quarter ending September 30, 2025, a decrease of -20.74%. This brings the company's revenue in the last twelve months to $9.05M, down -3.97% year-over-year. In the year 2024, COSCIENS Biopharma had annual revenue of $9.59M with 34.22% growth.
Revenue (ttm)
$9.05M
Revenue Growth
-3.97%
P/S Ratio
0.73
Revenue / Employee
$226.35K
Employees
40
Market Cap
4.94M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.59M | 2.44M | 34.22% |
| Dec 31, 2023 | 7.14M | -7.43M | -50.98% |
| Dec 31, 2022 | 14.57M | 9.31M | 177.03% |
| Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
| Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.02B |
COSCIENS Biopharma News
- 19 days ago - COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore - GlobeNewsWire
- 5 weeks ago - COSCIENS Biopharma Inc. Announces Leadership Change - GlobeNewsWire
- 4 months ago - COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update - GlobeNewsWire
- 6 months ago - COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders - GlobeNewsWire
- 7 months ago - COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - GlobeNewsWire
- 7 months ago - COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 9 months ago - COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 9 months ago - COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - GlobeNewsWire